Reaction
Sputum Retention reporting signals
As of the last recalculation, Sputum Retention appears in 965 FAERS reports alongside 26 co-occurring drug terms. The strongest observed disproportionality signal is AMIKACIN (PRR 96.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Amikacin | 71 | 96.8 | 97.2 |
| Theophylline | 19 | 36.4 | 36.4 |
| Theophylline Anhydrous | 19 | 33.7 | 33.7 |
| Mepolizumab | 66 | 30.7 | 30.7 |
| Ciclesonide | 16 | 25.7 | 25.8 |
| Dornase Alfa | 19 | 21.3 | 21.3 |
| Elexacaftor, Tezacaftor, And Ivacaftor | 12 | 21.0 | 21.0 |
| Rifampin | 14 | 21.0 | 21.0 |
| Ipratropium Bromide | 32 | 20.0 | 20.0 |
| Fluticasone Propionate And Salmeterol Xinafoate | 51 | 19.3 | 19.3 |
| Budesonide And Formoterol Fumarate Dihydrate | 75 | 18.0 | 18.0 |
| Azithromycin | 31 | 17.1 | 17.1 |
| Azithromycin Monohydrate | 31 | 16.6 | 16.6 |
| Tiotropium Bromide | 95 | 16.5 | 16.5 |
| Nintedanib | 21 | 14.7 | 14.8 |
| Tobramycin | 16 | 14.6 | 14.6 |
| Mirabegron | 22 | 12.5 | 12.5 |
| Rotigotine | 8 | 12.0 | 12.0 |
| Omalizumab | 45 | 11.9 | 11.9 |
| Fluticasone Furoate And Vilanterol Trifenatate | 17 | 10.4 | 10.4 |
| Lumacaftor And Ivacaftor | 4 | 10.1 | 10.1 |
| Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate | 18 | 9.5 | 9.5 |
| Umeclidinium Bromide And Vilanterol Trifenatate | 7 | 9.1 | 9.1 |
| Budesonide, Glycopyrrolate, And Formoterol Fumarate | 4 | 8.3 | 8.3 |
| Apalutamide | 4 | 7.4 | 7.4 |
| Palivizumab | 3 | 4.2 | 4.2 |